Home
News
Create
Screeners
Insights
Gujarat Terce Laboratories
43.
95
+0.88
(+2.04%)
Market Cap
₹14.08 Cr
PE Ratio
-
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.04%
1M
-14.33%
6M
-18.44%
1Y
-45.46%
5Y
+500.41%
View Company Insights
Latest news about Gujarat Terce Laboratories
Gujarat Terce Laboratories Reports Record EBITDA Despite Revenue Dip in Q2 FY26
Nov 08, 2025
Gujarat Terce Laboratories Limited achieved its highest-ever EBITDA of Rs 194.46 lacs in Q2 FY26, up 11.62% year-over-year, despite a 2.82% revenue decline to Rs 1,292.63 lacs. The EBITDA margin expanded to 15.04% from 13.10%. Net profit decreased by 5.30% to Rs 140.36 lacs. The company attributes the revenue reduction to planned scale-down of low-margin factory B2B sales and rationalization of non-profitable operations. Operating without external funding for three quarters, the pharmaceutical firm has a presence in 13 states with 8 leading brands across 134 products.
Gujarat Terce Laboratories Reports Q1 Loss, Reshuffles Board Committees
Aug 11, 2025
Gujarat Terce Laboratories Reports Net Loss Despite Revenue Growth, Settles Tax Disputes
Jul 26, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation